abstract BACKGROUND AND OBJECTIVES: Echocardiogram is the gold standard for the diagnosis of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm neonates. A simple blood assay for brain natriuretic peptide (BNP) or amino-terminal pro-B-type natriuretic peptide (NT-proBNP) may be useful in the diagnosis and management of hsPDA. Our objectives were to determine the diagnostic accuracy of BNP and NT-proBNP for hsPDA in preterm neonates and to explore heterogeneity by analyzing subgroups.
A symptomatic hemodynamically significant PDA (hsPDA) is often treated medically or by surgical closure. Echocardiogram is the gold standard for the diagnosis of hsPDA, but it is expensive and not always available in resource-limited settings. A simple blood assay that can diagnose hsPDA reliably will be useful to clinicians in such settings.
Brain natriuretic peptide (BNP) and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are synthesized and released into the circulation by the cardiac ventricular myocytes in response to pressure overload, volume expansion, and increase in myocardial wall stress. Within the myocytes, the precursor pro-BNP (108 amino acids) is converted to the biologically active form, BNP (77-108 amino acids) and the inactive NT-proBNP fragment (1-76 amino acids). BNP improves myocardial relaxation and regulates responses to acute increases in ventricular volume by opposing the vasoconstriction, sodium retention, and antidiuretic effects of the activated renin-angiotensinaldosterone system. 1 Plasma BNP and NT-proBNP are cleared by the kidneys and hence elevated in patients with renal failure. NT-proBNP has a longer half-life (60-120 minutes vs 22 minutes 2, 3 ) and is more stable in vitro. BNP and NT-proBNP are wellestablished markers of heart failure in adults 4,5 and children. 6 Many commercial kits are available for assessment of BNP and NT-proBNP, and levels reported vary with chronological age, gestational age (GA), PDA, and renal function.
The normative values of BNP and NT-proBNP in neonates from various studies are presented in Supplemental Table 3 . BNP and NT-proBNP values are highest in the first 3 days of life and decline progressively thereafter. 7, 8 Levels in preterm neonates are higher than in full-term neonates and are similar by 1 month of life. 9,10 NT-proBNP values are 6 to 20 times higher than BNP values, and the ratio between NT-proBNP and BNP is influenced by age. [11] [12] [13] [14] [15] [16] [17] BNP and NT-proBNP assays have been reported in the management of multiple neonatal conditions including hsPDA. 9,18-51 BNP and NT-proBNP have been used in preterm neonates both for diagnosis and to initiate medical or surgical treatment of hsPDA. The diagnostic accuracy of BNP and NT-proBNP in the management of hsPDA in neonates has not been systematically reviewed.
Our primary objective was to determine the diagnostic accuracy of cardiac biomarkers BNP and NT-pro-BNP in the diagnosis of hsPDA in preterm neonates.
The secondary objective was to explore heterogeneity among studies evaluating BNP and NT-proBNP by analyzing the following subgroups: commercial assay, test threshold, age of the patient at testing, GA at birth, and whether the test was used to initiate medical or surgical treatment.
METHODS
The method recommended by the Cochrane Diagnostic Test Accuracy Working Group was followed (http:// srdta.cochrane.org/). The title has been registered with the Cochrane Neonatal Review Group.
Criteria for Consideration of Studies for Review
Prospective and retrospective studies that evaluated blood BNP or NT-proBNP (index tests) in the diagnosis of PDA (target condition) in preterm neonates in conjunction with an echocardiogram (reference standard) were eligible for inclusion. Studies were excluded in which a threshold was not reported or could not be obtained from the authors.
There is no consensus for echocardiographic criteria for hsPDA. We chose 2 echocardiographic criteria to define hsPDA in preterm infants based on the best available evidence: LA/Ao ratio .1.5 and ductal diameter .1.5 mm (as measured by color Doppler), which are early predictors of hsPDA. 52 LA/Ao ratio is estimated from the diameter of the left atrium (LA) and from the aortic root diameter (Ao) in the parasternal long-axis view at the level of the aortic valve. [52] [53] [54] 
Search Strategy for Identification of Studies
We searched the following sources in April 2014 without any language restriction: 4. PubMed's related citations feature and relevant identified articles were searched.
5. The Science Citation Index was used to identify relevant articles by using previously identified articles.
6. Additional searches were made from reference lists in identified studies.
The search strategy is described in Supplemental Appendix 1.
Data Collection and Analyses

Selection of Studies
All titles and abstracts identified by our search strategy were screened for relevance by authors M.K. and M.P. together. All identified articles that were relevant to the review were retrieved in full and evaluated for inclusion eligibility by M.P. and M.K. independently. The results were compared and disagreements were resolved by mutual discussion.
Data Extraction and Management
Data extracted included author, year of publication and journal, study design, study population, reference standard and performance of the reference standard, index tests and performance of the index tests, information about quality assessment items based on Quality Assessment of Diagnostic-Accuracy Studies (QUADAS-2), 55 and data for 232 tables. Additional information to clarify the study design and data was sought from the authors via e-mail for $3 attempts. All the data were entered electronically on Microsoft Excel (Microsoft Corp, Redmond, WA) spreadsheets by M.P. and M.K. independently. The data extracted by each author were compared, and any discrepancies were resolved by mutual discussion and input from author C.J.F.
Assessment of Methodological Quality
The 
Investigations of Heterogeneity Among Studies
We investigated heterogeneity through subgroup analyses if data were available from $4 studies:
1. Type of commercial test assay used for BNP and NT-proBNP, because measurements may vary with each commercial assay.
2. Effects of age at testing: BNP and NT-proBNP levels are higher at birth and then decline over time.
3. Effects of GA: BNP and NT-proBNP levels are higher in preterm infants than in term infants.
FIGURE 1
Inclusion process for the systematic review based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses. a Review articles, animal studies, and studies that did not report outcomes of interest (congenital heart disease, intraventricular hemorrhage, transient tachypnea of the newborn, hypoxic-ischemic encephalopathy, respiratory distress syndrome) or did not evaluate BNP or NT-proBNP.
b Reasons for exclusion are listed in Table 2 . Others were 380 pg/mL, 450 pg/mL, 500 pg/mL*, 600 pg/mL, and 650 pg/mL.
• PDA with L → R shunt GA: 26 (25) (26) (27) 4. We determined whether the results of the test were used to initiate medical or surgical treatment of PDA.
5. Assay threshold cutoffs vary with the commercial assay and patient characteristics such as GA and chronological age.
RESULTS
We identified 82 records through database searches and 21 additional articles from conference abstracts and cross-referencing. The inclusion process is detailed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram (Fig 1) . Ten studies that evaluated BNP and 11 studies that evaluated NT-proBNP in the diagnosis of hsPDA met our inclusion criteria (Table 1) . Excluded studies and reasons for exclusion are described in Table 2 . Forest plots based on a single threshold from each study show that sensitivity across studies ranged from 0.60 to 1.0 for BNP and 0.58 to 1.0 for NT-proBNP, and specificity ranged from 0.6 to 1.0 for BNP and 0.57 to 1.0 for NT-proBNP (Fig 3) . We also plotted the included studies in the ROC space to give a sense of the distribution of the sensitivity and specificity of the studies (Fig 4) . We report the summary ROC curve, summary estimates of specificity and sensitivity, and the 95% confidence regions.
We analyzed subgroups of studies evaluating BNP and NT-proBNP based on the type of test kit, age at testing, and whether used to initiate medical or surgical treatment, and summary estimates are shown in Supplemental Risk of bias and applicability concerns graph based on QUADAS-2. Methodological assessment of included studies by QUADAS-2 method is presented. Review authors' judgments about each domain for risk of bias and applicability concerns presented as percentages across included studies: BNP (1st panel; 10 studies) and NT-proBNP (2nd panel; 11 studies). Studies with high risk of bias and applicability concerns are shown in red, those that are unclear in yellow, and those with low risk in green.
FIGURE 3
Sensitivity and specificity forest plots for BNP and NT-proBNP. This figure shows the forest plots of sensitivity and specificity along with covariates of assay type and threshold for BNP and NT-proBNP studies choosing a single threshold, ordered alphabetically. Each study is shown in a row, with the study year, TP, true positives; FP, false positives; FN, false negatives; TN, true negatives; assay, threshold, age, and sensitivity and specificity (blue squares) with 95% CI (black bars).
and pressure overload (maximum score 15) and clinical, radiologic, and laboratory features of both pulmonary overcirculation and systemic hypoperfusion. 65 In addition, only 34 of 90 eligible neonates were recruited in the study. A sensitivity analysis excluding the 2 studies by Elsayed et al 57,58 with unknown test kits, unknown exclusion criteria, PDA scores, and unaccountable total patients did not change our summary estimates of sensitivity and specificity significantly (summary sensitivity [0.87 vs 0.88] and specificity [0.89 vs 0.92]).
We attempted to explore heterogeneity on the basis of type of assay kit, age at testing, gestational age, threshold cutoffs, and whether indicated for medical or surgical closure. Data were insufficient to make any meaningful comparisons. There were wide variations in the threshold cutoffs in studies on BNP as well as NT-proBNP, possibly because of differences in assay characteristics or patient characteristics, which preclude recommendation of a specific threshold value of BNP or NT-proBNP for the diagnosis of hsPDA.
BNP and NT-proBNP assays are widely available and used in children and adults, both in hospitals and in the community, to diagnose or monitor cardiac failure in at-risk patients. [66] [67] [68] Many studies of BNP and NT-proBNP have been reported from the developing countries, in resource-limited settings. 10, 38, 59 The easy availability and its potential to complement echocardiography in the diagnosis of hsPDA or cardiac dysfunction in patients with bronchopulmonary dysplasia is likely to increase its usage in neonatal units, especially in resource-limited areas.
In adults, serial NT-proBNP estimations to guide therapy decrease mortality and hospitalization and decrease health care costs. [68] [69] [70] [71] However, studies that evaluated cost-effectiveness of BNP or NT-proBNP have not been reported in the neonatal population.
Strength and Weaknesses of the Review
Strengths
Our systematic review follows the method recommended by the Cochrane Diagnostic Test Accuracy Working Group. We searched comprehensively for all eligible studies by using clinically relevant inclusion criteria. We used the bivariate random effects model for meta-analyses of the included studies and strove to explain the sources of heterogeneity by subgroup analyses based on type of commercial assay, test threshold, age of the patient at testing, gestational age, and whether used for medical or surgical treatment of the PDA.
Weaknesses
Unlike meta-analyses of randomized control trials, heterogeneity is a wellrecognized problem in reviews of diagnostic test accuracy. 72 Despite our extensive search strategy, we may have missed potential studies, because diagnostic accuracy studies are poorly tagged in electronic databases. Publication bias in studies reporting diagnostic test accuracy has been poorly studied. 73 Poor reporting of study design, method of enrollment, and patient characteristics may hamper methodological assessment and external validity of the studies.
FIGURE 4
Studies of BNP and NT-proBNP are plotted in the ROC space. BNP studies are represented in blue ovals, NT-proBNP in red diamonds, and the size of the study symbols weighted for sample size. The summary curves (black line for BNP and red for NT-proBNP), summary points (black dot for BNP and red for NT-proBNP), and the 95% confidence region (dotted line) were derived from meta-analyses. Summary estimates at the summary point are as follows: BNP, sensitivity 88% and specificity 92%; NT-proBNP, sensitivity 90% and specificity 84%.
Another limitation of our review might be that echocardiogram (reference standard) parameters to diagnose hsPDA were not consistent between studies. A systematic review of the definition of hsPDA by echocardiogram highlights this issue in detail. 64 An ideal reference standard in the diagnosis of hsPDA may be a composite of echocardiographic, clinical, and radiographic findings, which must be evaluated and validated. 
Applicability of Findings to Clinical Practice and Policy
